ArticleThe open pain journal
Resiniferatoxin for Pain Treatment: An Interventional Approach to Personalized Pain Medicine.
Article in The open pain journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 59 citations in OpenAlex.
- Sex influences on tumor innervation.Biology of sex differences · 2026Article
- Mechanism of capsaicin entry into buried vanilloid sites in TRPV1.Nature chemical biology · 2025Article
- Chemical Components of the Dried Latex of Euphorbia resinifera Berg and Its Medicinal Features.Chemistry & biodiversity · 2025Review
- Efficient removal of naturally-occurring lipofuscin autofluorescence in human nervous tissue using high-intensity white light.The journal of pain · 2025Article
- Targeting TRPV1 channels in desensitized neural afferent pathways may help mitigate pain and lower urinary tract symptoms caused by prostatitis.Frontiers in pharmacology · 2025Article
- Syntaxin1A overexpression and pain insensitivity in individuals with 7q11.23 duplication syndrome.JCI insight · 2024Article
- Targeting TRPV1 for Cancer Pain Relief: Can It Work?Cancers · 2024Review
- The role of TRPV1 in chronic prostatitis: a review.Frontiers in pharmacology · 2024Review
- The metabolic and functional roles of sensory nerves in adipose tissues.Nature metabolism · 2023Review
- Anticancer Activity of Region B Capsaicin Analogs.Journal of medicinal chemistry · 2023Review
- Acute radiotherapy-associated oral pain may promote tumor growth at distant sites.Frontiers in oncology · 2023Article
- The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies.Acta pharmaceutica Sinica. B · 2022Review
- Anatomical Analysis of Transient Potential Vanilloid Receptor 1 (Frontiers in molecular neuroscience · 2022Article
- New Insights on the Role of TRP Channels in Calcium Signalling and Immunomodulation: Review of Pathways and Implications for Clinical Practice.Clinical reviews in allergy & immunology · 2021Review
- Review
- Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials.Frontiers in pharmacology · 2021Review
- Sensory Nociceptive Neurons Contribute to Host Protection During Enteric Infection With Citrobacter rodentium.The Journal of infectious diseases · 2020Article
- Comparative Analysis of Dorsal Root, Nodose and Sympathetic Ganglia for the Development of New Analgesics.Frontiers in neuroscience · 2020Article
- The Mysteries of Capsaicin-Sensitive Afferents.Frontiers in physiology · 2020Review
- Capsaicinoids: Multiple effects on angiogenesis, invasion and metastasis in human cancers.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
This review examines existing preclinical and clinical studies related to resiniferatoxin (RTX) and its potential uses in pain treatment. Like capsaicin, RTX is a vanilloid receptor (TRPV1) agonist, only more potent. This increased potency confers both quantitative and qualitative advantages in terms of drug action on the TRPV1 containing nerve terminal, which result in an increased efficacy and a long duration of action. RTX can be delivered by a central route of administration through injection into the subarachnoid space around the lumbosacral spinal cord. It can also be administered peripherally into a region of skin or deep tissue where primary afferents nerves terminate, or directly into a nerve trunk or a dorsal root ganglion. The central route is currently being evaluated as a treatment for intractable pain in patients with advanced cancer. Peripheral administration offers the possibility to treat a wide diversity of pain problems because of the ability to bring the treatment to the site of the pain (the peripheral generator). While not all pain disorders are appropriate for RTX, tailoring treatment to an individual patient's needs via a selective and local intervention that chemically targets a specific population of nerve terminals provides a new capability for pain therapy and a simplified and effective approach to personalized pain medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.